Yellow fever research hub

A Phase I, randomized, double-blind, multi-centre, placebo-controlled, dose-escalation study to evaluate the safety, reactogenicity and immunogenicity of AstriVax’ investigational vaccine for the prevention of yellow fever (AVX70120), and of AstriVax’ investigational vaccine for the prevention of rabies (AVX70481), in healthy adults aged 18 to 40 years.

This study is testing two new vaccines: one for yellow fever and one for rabies. It's the very first time these vaccines are being given to people. Researchers want to check if they are safe and if they create an immune response in healthy adults aged 18 to 40.